The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 451 participants.
Also called NCT01617434
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 451 participants
- Sponsor
- Registry
-
NCT01617434 -
2011-002696-41
-
- Other papers using this trial's data
- Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Canada, Finland, Germany, India, Mexico, Netherlands, Serbia
- Registry status
- Completed
Technical summary
Registry record NCT01617434. Randomized; double masking; primary purpose treatment. Start 2012-09 (registry gives no type); primary completion 2013-10 (actual). Results posted on 2014-10-28.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- liraglutide
- Intervention (Drug)
- placebo
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01617434- Content hash
4ff75964b4e27942a1110cb048de118f0c8d76f409194808bc4b83b587234442